Charles River Laboratories First Quarter 2026 Results were officially released, showcasing a company in the midst of a significant strategic transformation. The Wilmington-based contract research organization reported a total revenue of $995.8 million for the period ending March 28, 2026, marking a 1.2% increase compared to the previous year. Despite a GAAP net loss attributed to the completion of major divestitures, the company exceeded analyst expectations for its adjusted earnings.
Financial Overview of Charles River Laboratories First Quarter 2026 Results
On a GAAP basis, the company reported a net loss available to common shareholders of $(14.8) million, or $(0.30) per diluted share. This decline from the prior year’s profit was primarily driven by a $118.0 million loss on assets held for sale related to the divestiture of its CDMO and Cell Solutions businesses.
However, the non-GAAP Charles River Laboratories First Quarter 2026 Results tell a more positive story for investors. The non-GAAP diluted earnings per share (EPS) came in at $2.06, surpassing the consensus estimate of $1.96. While this was a 12.0% decrease from the $2.34 reported in Q1 2025, it reflects the company’s ability to navigate a shifting biotech landscape.
Segment Performance and Organic Revenue Growth
Within the Charles River Laboratories First Quarter 2026 Results, the company highlighted mixed performance across its core segments. The Manufacturing Solutions segment was the standout performer, with a 6.8% revenue increase driven by strong demand in Microbial Solutions.
Conversely, the Research Models and Services (RMS) and Discovery and Safety Assessment (DSA) segments faced headwinds. Organic revenue for the entire company declined by 1.5%, as higher study-related costs and unfavorable revenue mixes offset growth in other areas.
Strategic Milestones and 2026 Guidance
A pivotal highlight of the Charles River Laboratories First Quarter 2026 Results announcement was the completion of the divestiture of the CDMO and Cell Solutions businesses to GI Partners on May 6, 2026. This move is part of the “Pathway to Purpose” strategy led by the newly appointed CEO, Birgit Girshick, aimed at sharpening the company’s focus on its core drug discovery and safety assessment capabilities.
The company also reaffirmed its full-year 2026 guidance, expecting non-GAAP EPS to remain between $10.80 and $11.30.
Key Financial Indicators (Q1 2026 vs Q1 2025)
| Metric | Q1 2026 (Actual) | Q1 2025 (Actual) | Year-over-Year Change |
| Total Revenue | $995.8M | $984.2M | +1.2% |
| Organic Revenue Growth | (1.5)% | N/A | – |
| GAAP EPS | $(0.30) | $0.50 | -160.0% |
| Non-GAAP EPS | $2.06 | $2.34 | (12.0)% |
| GAAP Operating Margin | 12.0% | 7.6% | +440 bps |
| Non-GAAP Operating Margin | 16.3% | 19.1% | (280) bps |
| Stock Repurchases | $200.0M | $0.0M | N/A |
Revenue Performance by Segment
| Segment | Q1 2026 Revenue | Organic Growth | GAAP Operating Margin |
| Discovery & Safety (DSA) | $596.9M | (1.4)% | 17.4% |
| Research Models (RMS) | $208.4M | (5.5)% | 23.9% |
| Manufacturing Solutions | $190.5M | +2.9% | 25.9% |
Full-Year 2026 Financial Guidance
| Category | 2026 Guidance Range | Status |
| Reported Revenue Growth | (5.5)% – (4.0)% | Reaffirmed |
| Organic Revenue Growth | (1.5)% – (0.5)% | Reaffirmed |
| GAAP EPS Estimate | $5.35 – $5.85 | New |
| Non-GAAP EPS Estimate | $10.80 – $11.30 | Reaffirmed |
| Free Cash Flow | $375M – $400M | Reaffirmed |
